Cargando…
Molecular Genetics Overview of Primary Mitochondrial Myopathies
Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836969/ https://www.ncbi.nlm.nih.gov/pubmed/35160083 http://dx.doi.org/10.3390/jcm11030632 |
_version_ | 1784649808352378880 |
---|---|
author | Arena, Ignazio Giuseppe Pugliese, Alessia Volta, Sara Toscano, Antonio Musumeci, Olimpia |
author_facet | Arena, Ignazio Giuseppe Pugliese, Alessia Volta, Sara Toscano, Antonio Musumeci, Olimpia |
author_sort | Arena, Ignazio Giuseppe |
collection | PubMed |
description | Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts in Mitochondrial Diseases held in Rome in 2016, the term Primary Mitochondrial Myopathy (PMM) should refer to those mitochondrial disorders affecting principally, but not exclusively, the skeletal muscle. The clinical presentation may include general isolated myopathy with muscle weakness, exercise intolerance, chronic ophthalmoplegia/ophthalmoparesis (cPEO) and eyelids ptosis, or multisystem conditions where there is a coexistence with extramuscular signs and symptoms. In recent years, new therapeutic targets have been identified leading to the launch of some promising clinical trials that have mainly focused on treating muscle symptoms and that require populations with defined genotype. Advantages in next-generation sequencing techniques have substantially improved diagnosis. So far, an increasing number of mutations have been identified as responsible for mitochondrial disorders. In this review, we focused on the principal molecular genetic alterations in PMM. Accordingly, we carried out a comprehensive review of the literature and briefly discussed the possible approaches which could guide the clinician to a genetic diagnosis. |
format | Online Article Text |
id | pubmed-8836969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88369692022-02-12 Molecular Genetics Overview of Primary Mitochondrial Myopathies Arena, Ignazio Giuseppe Pugliese, Alessia Volta, Sara Toscano, Antonio Musumeci, Olimpia J Clin Med Review Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts in Mitochondrial Diseases held in Rome in 2016, the term Primary Mitochondrial Myopathy (PMM) should refer to those mitochondrial disorders affecting principally, but not exclusively, the skeletal muscle. The clinical presentation may include general isolated myopathy with muscle weakness, exercise intolerance, chronic ophthalmoplegia/ophthalmoparesis (cPEO) and eyelids ptosis, or multisystem conditions where there is a coexistence with extramuscular signs and symptoms. In recent years, new therapeutic targets have been identified leading to the launch of some promising clinical trials that have mainly focused on treating muscle symptoms and that require populations with defined genotype. Advantages in next-generation sequencing techniques have substantially improved diagnosis. So far, an increasing number of mutations have been identified as responsible for mitochondrial disorders. In this review, we focused on the principal molecular genetic alterations in PMM. Accordingly, we carried out a comprehensive review of the literature and briefly discussed the possible approaches which could guide the clinician to a genetic diagnosis. MDPI 2022-01-26 /pmc/articles/PMC8836969/ /pubmed/35160083 http://dx.doi.org/10.3390/jcm11030632 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Arena, Ignazio Giuseppe Pugliese, Alessia Volta, Sara Toscano, Antonio Musumeci, Olimpia Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title | Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title_full | Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title_fullStr | Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title_full_unstemmed | Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title_short | Molecular Genetics Overview of Primary Mitochondrial Myopathies |
title_sort | molecular genetics overview of primary mitochondrial myopathies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836969/ https://www.ncbi.nlm.nih.gov/pubmed/35160083 http://dx.doi.org/10.3390/jcm11030632 |
work_keys_str_mv | AT arenaignaziogiuseppe moleculargeneticsoverviewofprimarymitochondrialmyopathies AT pugliesealessia moleculargeneticsoverviewofprimarymitochondrialmyopathies AT voltasara moleculargeneticsoverviewofprimarymitochondrialmyopathies AT toscanoantonio moleculargeneticsoverviewofprimarymitochondrialmyopathies AT musumeciolimpia moleculargeneticsoverviewofprimarymitochondrialmyopathies |